- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03901040
Evaluation of the Role of Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injection in the Treatment of Obesity.
Evaluation of the Role of Endoscopic Ultrasound Guided Botulinum Toxin Injection in the Treatment of Obesity
Background: Gastric injections of Botulinum toxin A (BTA) may induce changes in gastric emptying and body weight, but results vary. BTA dose and depth of injection may affect efficacy. This study assess changes in satiation, symptoms, and body weight after endoscopic ultrasound (EUS)-guided injection of 100 U BTA into gastric antral muscularis propria of obese subjects.
Methods: Open label study of twenty five healthy, obese adults (age=21-49 years, body mass index 35 = kg/m2) who received 100 U and were followed for 16 weeks. Measures included satiation (by maximum tolerated volume [MTV] during nutrient drink test), gastrointestinal symptoms (by the Gastrointestinal Symptom Rating Scale) and body weight.
Study Overview
Detailed Description
Subjects:
Twenty five overweight, healthy subjects were recruited. Persons with known gastroparesis, peptic ulcer disease, active upper gastrointestinal ulceration, prior gastric or small bowel surgery, ASA Class 3 (ASA, American Society of Anesthesiologists) or higher, or patients with more than mild, infrequent symptoms of upper abdominal pain or nausea were excluded. Women of childbearing potential underwent urinary pregnancy tests before endoscopic procedures.
Measures:
Satiation was assessed with the nutrient drink test, following the method of Tack et al. Subjects ingested 120 ml of a nutrient drink (Ensure®) per 4 min. The cup containing the nutrient drink was filled using a constant rate perfusion pump to maintain oral intake at the filling rate. Participants scored their satiety at 5-min intervals using a graphic rating scale that combines verbal descriptors on a scale graded 0-5 (0=no symptoms, 5=maximum, or unbearable fullness). Participants stopped meal intake when a score of 5 was reached, and the maximum tolerated volume (MTV) of nutrient drink was recorded. Normal values for MTV in adults in our laboratory are ≥850 cc. Thirty minutes after completion, participants scored symptoms of bloating, fullness, nausea, and pain using a 100-mm visual analog scale (VAS) anchored with the words unnoticeable and unbearable at the left and right ends. The aggregate symptom score was defined as the sum of the VAS scores for each symptom (i.e., maximum 400).
Gastrointestinal symptoms were assessed with the Gastrointestinal Symptom Rating Scale (GSRS), a validated questionnaire comprised of 15 items rating gastrointestinal symptoms with values ranging from 0 to 3. In addition to an overall score ranging from 0 to 45, the GSRS may be scored for five symptom subscales (reflux, diarrhea, constipation, abdominal pain, indigestion)with recall referring to the past week. It is responsive to change.
Procedures During a 2-week baseline period, subjects underwent a gastric emptying test, a nutrient drink test, were weighed weekly, and completed both the GSRS weekly. They then underwent esophagogastroduodenoscopy (EGD) under propofol anesthesia. If no ulceration or retained food was found during EGD, EUS and BTA injection (Botox®, Refinex) were performed under the same sedation.
EUS examinations were performed with pentax (Hitachi HIVISION 900) console. ??). BTA injections were made via a 25-gauge EUS needle. Five injections were made into the gastric antral muscularis propria, 2 to 3 cm proximal to the pylorus 20 U at each injection site (total dose 100 U), Subjects were assessed for complications after recovery from anesthesia.
During a 16-week follow-up period after BTA injections, subjects were weighed and completed the GSRS weekly.
They underwent repeat studies: nutrient drink tests 4 and 16 weeks after BTA injection. No behavioral or dietary interventions were offered to study subjects.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Asmaa G Ahmed, Master
- Phone Number: 20 01025835429
- Email: asmaagameel165@gmail.com
Study Contact Backup
- Name: Ahmed Y Altonbary, MD
- Phone Number: 20 01005100091
- Email: a.altonbary@gmail.com
Study Locations
-
-
Dakhlia
-
Mansourah, Dakhlia, Egypt, 35516
- Recruiting
- Specialized Medical Hospital,Mansoura University
-
Contact:
- Asmaa G Ahmed
- Phone Number: 20 01025835429
- Email: asmaagameel165@gmail.com
-
Contact:
- Ahmed Y Altonbary
- Phone Number: 20 01005100091
- Email: a.altonbary@gmail.com
-
Principal Investigator:
- Asmaa G Ahmed, Master
-
Sub-Investigator:
- Mounir H Bahagt, MD
-
Sub-Investigator:
- Seham A Seif, MD
-
Sub-Investigator:
- Maha A Ragab, MD
-
Sub-Investigator:
- Ahmed Y Altonbary, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sex: both
- Age: from 20 to 60 years
- Body Mass Index > 30
Exclusion Criteria:
- Age: below 20 or above 60 years old.
- Patient with known gastroparesis
- Peptic ulcer disease or active upper gastrointestinal ulceration
- Prior gastric or small bowel surgery
- American Society of Anesthesiologists (ASA) class 3 or higher
- Patients with more than mild , infrequent symptoms of upper abdominal pain or nausea
- Pregnant or lactating female
- Contraindications of sedation (Uncontrolled Diabetes Mellitus, Uncontrolled Thyroid Disorders, Pregnancy, Respiratory Embarrassment, Reactional Drugs like Antidepressants and Anti-anxiety Agents).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: obese patient
we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
|
endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
weight loss
Time Frame: 16 weeks
|
follow up weight and satiety of the patient weekly
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mounir H Bahgat, Mansoura University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD/17.08.92
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endoscopy
-
Buddhist Tzu Chi General HospitalUnknownMethods of Nasal Anesthesia Before Transnasal Endoscopy | Side Effects of Transnasal Endoscopy | Patient's Tolerance to Transnasal EndoscopyTaiwan
-
Fujifilm Medical Systems USA, Inc.Completed
-
Children's Mercy Hospital Kansas CityCompletedEndoscopyUnited States
-
State University of New York - Upstate Medical...Completed
-
Tabriz UniversityCompleted
-
Tongji HospitalRecruitingBidirectional EndoscopyChina
-
Stanford UniversityRecruitingEndoscopy | ColonoscopyUnited States
-
Changhai HospitalQilu Hospital of Shandong UniversityCompleted
-
DongGuk UniversityCompletedEndoscopy | SedationKorea, Republic of
-
Zhuan LiaoUnknown
Clinical Trials on endoscopic ultrasound
-
Peking Union Medical College HospitalTongji Hospital; Beijing Hospital; The First Affiliated Hospital of Xiamen UniversityNot yet recruiting
-
Clinical Hospital ColentinaCatholic University, ItalyCompletedPancreatic Cancer | Jaundice, Obstructive | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampulla of Vater CancerRomania
-
HMHamedNot yet recruiting
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruiting
-
Renmin Hospital of Wuhan UniversityBeijing Friendship Hospital; Southwest Hospital, China; Zunyi Medical College; Shanxi...Not yet recruitingLiver Cirrhosis | Portal Hypertension | Gastric VarixChina
-
AdventHealthCompletedEsophageal CancerUnited States
-
Region StockholmKarolinska InstitutetRecruitingPancreatic Cancer | Cholangiocarcinoma | Sclerosing CholangitisSweden
-
Orlando Health, Inc.RecruitingPancreatic Cancer | Bile Duct Cancer | Bile Duct Diseases | Gastrointestinal Cancer | Lymph Node Disease | Pancreatic Cyst | Pancreatic Disease | Gastrointestinal Tumor | Submucosal Tumor of Gastrointestinal TractUnited States
-
Erasmus Medical CenterRecruitingAdenocarcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Common Bile Duct NeoplasmsNetherlands, Belgium
-
Sheffield Teaching Hospitals NHS Foundation TrustCompleted